The Cooper Companies
The Cooper Companies, Inc.
Key figures
Period Nov 2024 to Oct 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$4.1B
Operating marginCalculated
16.7%
Net assets to total assetsCalculated
66.5%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★★★★☆position among all companies
16.7%
Growth (revenue, 4-year average)
★★★★☆position among all companies
8.8%
Capital efficiency
★★☆☆☆position among all companies
4.6%
Revenue and profit
Performance, financial position and capital allocation
The Cooper Companies
Recent performance trends
The Cooper Companies
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$2.9 billion | US$3.3 billion | US$3.6 billion | US$3.9 billion | US$4.1 billion |
| Operating income | US$0.5 billion | US$0.5 billion | US$0.5 billion | US$0.7 billion | US$0.7 billion |
| Net income | US$2.9 billion | US$0.4 billion | US$0.3 billion | US$0.4 billion | US$0.4 billion |
| Total assets | US$9.6 billion | US$11.5 billion | US$11.7 billion | US$12.3 billion | US$12.4 billion |
| Shareholders' equity | US$6.9 billion | US$7.2 billion | US$7.6 billion | US$8.1 billion | US$8.2 billion |
| Net cash provided by (used in) operating activities | US$0.7 billion | US$0.7 billion | US$0.6 billion | US$0.7 billion | US$0.8 billion |
| Net cash provided by (used in) investing activities | US$-0.5 billion | US$-1.8 billion | US$-0.4 billion | US$-0.8 billion | US$-0.4 billion |
| Net cash provided by (used in) financing activities | US$-0.3 billion | US$1.2 billion | US$-0.2 billion | US$39.20 million | US$-0.4 billion |
| Cash and cash equivalents | US$95.90 million | US$0.1 billion | US$0.1 billion | US$0.1 billion | US$0.1 billion |
Revenue scale in the same industry
The Cooper Companies
Instruments and medical devices: 43 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Thermo Fisher ScientificFY Dec 2025 US$44.6B
- 2 Northrop Grumman Corp /DE/FY Dec 2025 US$42.0B
- 3 MedtronicFY Apr 2026 US$36.4B
- … 27 companies
- 31 FortiveFY Dec 2025 US$4.2B
- 32 HologicFY Sep 2025 US$4.1B
- 33 The Cooper CompaniesThis companyFY Oct 2025 US$4.1B
- 34 Align TechnologyFY Dec 2025 US$4.0B
- 35 Mettler-Toledo InternationalFY Dec 2025 US$4.0B
- … 8 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.4 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$0.1 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-0.4 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-0.4 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$0.8 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$0.4 billion | Consolidated | Disclosed |
| Dividends paid | US$0 | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$8.2 billion | Consolidated | Disclosed |
| Non-controlling interests | US$0.20 million | Consolidated | Disclosed |
| Net assets | US$8.2 billion | Consolidated | Disclosed |
| Net sales | US$4.1 billion | Consolidated | Disclosed |
| Operating income | US$0.7 billion | Consolidated | Disclosed |
| Net income | US$0.4 billion | Consolidated | Disclosed |
| Total assets | US$12.4 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$0.3 billion | Consolidated | Disclosed |
| Operating margin | 16.7% | Consolidated | Calculated |
| Net assets to total assets | 66.5% | Consolidated | Calculated |
| Net margin | 9.2% | Consolidated | Calculated |
| Return on equity | 4.6% | Consolidated | Calculated |